• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Not Available].

作者信息

Caprioli Flavio, Fantini Massimo Claudio, Marando Francesca, Scaduto Dario, Ravasio Roberto

机构信息

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano - Italy Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milano - Italy.

Department of Medical Science and Public Health, University of Cagliari, Cagliari - Italy Azienda Ospedaliero-Universitaria (AOU) di Cagliari, Cagliari - Italy.

出版信息

Glob Reg Health Technol Assess. 2024 Mar 7;11:55-67. doi: 10.33393/grhta.2024.2658. eCollection 2024 Jan-Dec.

DOI:10.33393/grhta.2024.2658
PMID:38469393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10926000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/ed5bcbe1fcf6/grhta-11-55_g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/1453e3f1065c/grhta-11-55_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/be6ad0412c5a/grhta-11-55_g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/bcf5beb6ac0f/grhta-11-55_g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/095fcaadebc0/grhta-11-55_g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/04ea4a66fbf3/grhta-11-55_g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/50ed372e43a2/grhta-11-55_g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/0c81a39a4aba/grhta-11-55_g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/b10aaf1efcb2/grhta-11-55_g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/feb7b86c587c/grhta-11-55_g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/a5d22fb1d50c/grhta-11-55_g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/0c6b99e269d4/grhta-11-55_g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/4329abb75409/grhta-11-55_g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/ed5bcbe1fcf6/grhta-11-55_g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/1453e3f1065c/grhta-11-55_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/be6ad0412c5a/grhta-11-55_g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/bcf5beb6ac0f/grhta-11-55_g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/095fcaadebc0/grhta-11-55_g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/04ea4a66fbf3/grhta-11-55_g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/50ed372e43a2/grhta-11-55_g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/0c81a39a4aba/grhta-11-55_g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/b10aaf1efcb2/grhta-11-55_g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/feb7b86c587c/grhta-11-55_g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/a5d22fb1d50c/grhta-11-55_g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/0c6b99e269d4/grhta-11-55_g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/4329abb75409/grhta-11-55_g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994c/10926000/ed5bcbe1fcf6/grhta-11-55_g013.jpg

相似文献

1
[Not Available].[无可用内容]
Glob Reg Health Technol Assess. 2024 Mar 7;11:55-67. doi: 10.33393/grhta.2024.2658. eCollection 2024 Jan-Dec.

本文引用的文献

1
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.中重度活动性溃疡性结肠炎诱导和维持期先进疗法的疗效与安全性：一项使用贝叶斯网络荟萃分析的间接治疗比较
Crohns Colitis 360. 2023 Mar 1;5(2):otad009. doi: 10.1093/crocol/otad009. eCollection 2023 Apr.
2
Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.比较中重度溃疡性结肠炎的早期症状缓解速度与先进治疗方法：系统评价和网络荟萃分析。
Am J Gastroenterol. 2023 Sep 1;118(9):1618-1625. doi: 10.14309/ajg.0000000000002263. Epub 2023 Mar 29.
3
Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.《克罗恩病和溃疡性结肠炎中先进疗法的剂量递增模式：系统文献回顾》
Adv Ther. 2023 May;40(5):2051-2081. doi: 10.1007/s12325-023-02457-6. Epub 2023 Mar 17.
4
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
5
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.生物疗法和小分子药物治疗中重度溃疡性结肠炎的疗效：系统评价与网状Meta分析
Gut. 2021 Dec 22. doi: 10.1136/gutjnl-2021-326390.
6
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.生物制剂和小分子药物治疗中重度溃疡性结肠炎患者的疗效和安全性：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29.
7
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy.乌司奴单抗治疗溃疡性结肠炎的一年疗效和安全性：来自意大利的多中心真实世界研究。
Expert Opin Biol Ther. 2021 Nov;21(11):1483-1489. doi: 10.1080/14712598.2021.1981855. Epub 2021 Sep 27.
8
JAK1 inhibition and inflammatory bowel disease.JAK1 抑制与炎症性肠病。
Rheumatology (Oxford). 2021 May 5;60(Supple 2):ii45-ii51. doi: 10.1093/rheumatology/keaa896.
9
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
10
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.维得利珠单抗在生物初治患者中的有效性和安全性：一项真实世界多中心研究。
United European Gastroenterol J. 2020 Nov;8(9):1045-1055. doi: 10.1177/2050640620948802. Epub 2020 Aug 9.